Developing WePrEP A Bilingual Tool to Help Transgender Women and Providers Choose the Best HIV Prevention Method

What this Trial Is About

Researchers are evaluating a bilingual digital shared decision-making tool called WePrEP, designed to improve communication between transgender women and their HIV pre-exposure prophylaxis PrEP service providers. The study focuses on helping transgender women choose the most suitable PrEP method, either oral or injectable cabotegravir CAB-LA, by addressing their unique concerns and enhancing adherence. This tool aims to support diverse English- and Spanish-speaking transgender women and their providers in selecting the best PrEP option for each individual. The study involves a randomized controlled trial with 69 transgender women assigned in a 21 ratio to either use WePrEP with their providers or receive standard care explanations based on CDC guidelines. Providers in the intervention group will use WePrEP on tablets to present key information and guide discussions about PrEP options and adherence strategies. Control group providers will give standard PrEP explanations without the tool. Providers will use WePrEP with multiple participants to provide feedback during the study. Participants will undergo assessments at enrollment and follow-up visits, including measuring feasibility and acceptability of WePrEP, as well as preliminary impact measures such as PrEP uptake, serum concentrations, and adherence behavior. Patient-provider communication, satisfaction, engagement, and shared decision-making will also be evaluated using validated scales and qualitative methods. The trial runs from early 2025 through 2027, with ongoing monitoring of outcomes relevant to PrEP use in transgender women.

WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women